KIDS — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-01

• We currently market nearly 90 surgical and specialized bracing systems that serve three of the largest categories within the pediatric orthopedic market: (i) trauma and deformity correction, (ii) scoliosis and (iii)

• sports medicine. We manufacture the majority of our orthopedic bracing products and we rely on a broad network of third parties to manufacture the components of our surgical products, which we then inspect and package. We believe our innovative products promote improved surgical accuracy, increase c…

• The majority of our revenue from implants, instruments, and specialized braces has been generated in the United States. Our global sales management organization leads a network of sales agencies, stocking distributors as well as direct sales representatives. We sell our implants and instruments thro…

• We market and sell our products internationally in over 75 countries, through independent stocking distributors and sales agencies. Our independent distributors manage the billing relationship with each hospital in their respective territories and are responsible for servicing the product needs of t…

• Our global inventory, which primarily consists of implants and instruments held in our warehouses, with

Text removed vs the prior filing · source: 10-Q · 2025-10-29

• We currently market 82 surgical and specialized bracing systems that serve three of the largest categories within the pediatric orthopedic market: (i) trauma and deformity correction, (ii) scoliosis and (iii) sports medicine. We manufacture the majority of our orthopedic bracing products and we rely…

• The majority of our revenue from implants, instruments, and specialized braces has been generated in the United States. Our global sales management organization leads a network of sales agencies, stocking distributors as well as direct sales representatives. We sell our implants and instruments thro…

• We market and sell our products internationally in over 75 countries, through independent stocking distributors and sales agencies. Our independent distributors manage the billing relationship with each hospital in their respective territories and are responsible for servicing the product needs of t…

• Our global inventory, which primarily consists of implants and instruments held in our warehouses, with third-party independent sales agencies or distributors, or consigned directly with hospitals, are

• Three Months Ended September 30,Nine Months Ended September 30,

Text added vs the prior filing · source: 10-Q · 2026-05-01

• All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and…

• •our ability to achieve or sustain profitability in the future;

• •our ability to raise additional capital to fund our existing commercial operations, develop and commercialize new products and expand our operations;

• •our ability to commercialize our products in development and to develop and commercialize additional products through our research and development efforts, and if we fail to do so we may be unable to compete effectively;

• •our ability to generate sufficient revenue from the commercialization of our products to achieve and sustain profitability;

Text removed vs the prior filing · source: 10-Q · 2025-10-29

• In addition to the other information set forth in this quarterly report, you should carefully consider the factors discussed in “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 5, 2025. Other than as described below, there have been no material changes to these Risk Facto…

• We are subject to risks of doing business in other countries, including those related to tariffs, trade restrictions and government actions.

• We are subject to risks of doing business internationally, including:

• •changes in regulatory requirements or other executive branch actions, such as Executive Orders;

• •changes in the global trade environment, including potential deterioration in geopolitical or trade relations between countries;